Innovative strategies and models for r&d success: the evolving networked pharma company—aarkstore enterprise

Innovative Strategies and Models for R&D Success: The evolving networked pharma company—Aarkstore Enterprise

Aarkstore announce a new report » Innovative Strategies and Models for R&D Success: The evolving networked pharma company » through its vast collection of market research report.

Innovative Strategies and Models for R&D Success The evolving networked pharma company
Report overview

Many pharma companies are currently engaged in wide-scale R&D restructuring, adopting a biotechnological approach to drug development by establishing disease-focused R&D units, R&D spin-offs, strategic partnerships and joint ventures. This trend has been reinforced by the emergence of public/private partnerships, co-operatives and open-source research initiatives that have encouraged companies to target previously neglected disease areas such as biotherapeutics and vaccines. Emerging markets are also driving change throughout R&D, with companies increasingly internationalizing their processes to take advantage of tax incentives, government investment, cheap labor and technology specialists.
‘Innovative Strategies and Models for R&D Success’ is a new report explores how the latest pharma R&D strategies are improving productivity and containing costs. The effectiveness of new and emerging approaches to drug discovery and development are assessed, with over 40 detailed case studies of partnerships, alliances, collaborations, outsourcing and in-licensing opportunities. This report also explores the potential benefits and disadvantages of key offshore markets including China, India and Russia and examines the recent internal restructurings of major companies such as AstraZeneca, GlaxoSmithKline, Pfizer and Roche.
Use over 40 detailed case studies to assess new R&D approaches, and identify which strategies are most effective for different company sizes, therapeutic area focus, product portfolios and geographical locations…
Key findings

• The pharma industry is migrating towards fully-integrated networked pharmaceutical companies (FINPCos) that can improve productivity and effectively exploit the cost-savings associated with R&D internationalization. This model maximizes investment returns through the use of innovative partnerships and strategic alliances.
• Major companies including AstraZeneca, GSK, Roche and Pfizer have recenty undertaken major R&D restructuring. Changes have typically involved strategic risk-sharing partnerships, collaborations, joint ventures, spin-offs and contract agreements.
• Big Pharma are increasingly engaging in a range of risk-sharing partnerships with academics, federal agencies, contract providers, biotechs and other pharma players. Such alliances alleviate the risks of drug discovery and can improve R&D efficiency.
• Up to 30% of clinical studies are currently outsourced, and this figure will rise to 50% by 2010. This growth will be driven by companies consolidating their focus upon core competencies while contracting out secondary R&D programs to specialists.
• Virtual pharma models can reduce drug development costs by at least 25% and development times by up to 50%. Niche pharma companies have emerged to add value through strategic outsourced clinical developments that are out-licensed to established players.
Key questions answered

• What are public private partnerships and how can they be used to expand R&D programs?
• How will private federal partnerships improve technology transfer to the industry?
• To what extent can R&D outsourcing reduce development times and contain costs?
• Who are the key contract service providers in the emerging markets and what R&D related services do they offer?
• Which alternative R&D strategies are being used to attract investment and drive product development?
• How can pharma companies most effectively ensure shareholder value in the future?
Key issues examined by this report

• Benefits of R&D restructuring. The redesign of pharma R&D models within large companies is creating an entrepreneurial environment that enhances the flow of information and facilitates faster decision-making during product development. Strategic networking is also helping companies to expand their portfolios and develop a new generation of progressive blockbusters.
• New R&D approaches reduce consolidation. Innovative R&D strategies such as risk-sharing partnerships and strategic/tactical outsourcing are helping to combat the declining levels of productivity that are driving industrial consolidation.
• Role of ‘R&D spin-offs’. R&D spin-offs enable pharma companies to streamline their portfolios and reduce overheads, whilst retaining the option to license back successful candidates at a future date. The speed of product development can also be significantly improved away from internal pharma processes.
• Influence of emerging markets. Offshore R&D investments in emerging countires are becoming increasingly attractive following the lifting of WTO restrictions, tightened IP protections, infrastructure improvements and tax exemptions. India, China and Russia offer the most significant cost advatages.

For more information, please visit :
http://www.aarkstore.com/reports/Innovative-Strategies-and-Models-for-R-D-Success-The-evolving-networked-pharma-company-14339.html
Or email us at press@aarkstore.com or call +919272852585

Special offer till 31th Dec 2009

Internal meditation can also make your heart happy…

Internal Meditation Can Also Make Your Heart Happy…………

Meditation is good for your heart. This is the message recently (in the year of 2006) conveyed by the Archives of Internal Medicine. The study reported that transcendental meditation (TM), a relaxation technique reduced the risk factors of coronary heart disease in a 4-month clinical trial. Significantly reduced insulin resistance and lower blood pressure were found for patients who meditated. These patients also had more stables functioning of the autonomic nervous system that controls heart and other involuntary muscles.

There is closed relationship between stress, meditation, and heart health. It is evident that severe emotional and physical stress raises adrenalin levels or sympathetic drive, which in turn can lead to higher blood pressure or in worst case, may even transiently impair the ability of the heart to contract well. Stress can also cause the body to become less responsive to insulin, which is a hormone that controls the amount of sugar in the body. If you are already pre-diabetic or have metabolic syndrome, risk factors for heart disease, this condition will worsen. Meditation or any activity that can reduce stress levels is useful to improve blood pressure or metabolic syndrome.

What affect your brain is connected to what your heart functions. Emotional distress affects part of the brain function, which affects the sympathetic drive and so, the heart. The happier your brain is, the better your heart functions.

What is meditation? This is simply the practice of closing your eyes and focusing on your breathing as you go into a state of deep rest. It is a technique that can benefit not only your mind but also your body. It can actually reduce your risk of collapsing from heart problems by modulating your body’s response to stress. In short, meditation is a practice that involves calming your mind and body.

TM is an effortless technique practiced for about 15 to 20 minutes twice daily. It allows a person to attain deep rest for the body and mind. A suitable time to meditate is when the person is not feeling tired, hungry, or irritated. He or she should feel comfortable and be in a positive frame of mind.

Drugs cannot effectively reduce stress levels and should not be considered as the primary approach. A happy, spiritual or emotional heart is basically good medicine. This is an advice from a friend of mine who is also a consultant cardiologist. So, perhaps you may wish to consider meditation as one of the alternatives to help you reduce your stress level.

Did you find this article useful? For more useful tips and hints, points to ponder and keep in mind, techniques, and insights pertaining to Internet Business, do please browse for more information at our websites.
<a href=»http://www.adsence-dollar-factory.com»>http://www.adsence-dollar-factory.com</a>
<a href=»http://www.100earningtips.com»>http://www.100earningtips.com</a>

Ipsen s

Ipsen S.a. — Swot Analysis — Market Research Reports On Aarkstore Enterprise

Ipsen S.A. — SWOT Analysis company profile is the essential source for top-level company data and information. Ipsen S.A. — SWOT Analysis examines the company’s key business structure and operations, history and products, and provides summary analysis of its key revenue lines and strategy.
Ipsen is a global pharmaceutical group with over 20 products in targeted therapeutic areas such as oncology, endocrinology, neurology and haematology. It also produces primary care drugs. The group primarily operates in Europe. It is headquartered in Boulogne-Billancourt, France and employed 4,277 people as of December 2008. The group recorded revenues of E1,038.1 million ($1,527.4 million) during the financial year (FY) ended December 2008, an increase of 4.5% over FY2007. The increase in revenues was due to higher sale of specialty care drugs such as Somatuline, Smecta, NutropinAq, Dysport and Decapeptyl. The operating profit of the group was E180.1 million ($265 million) during FY2008, a decrease of 13.8% over FY2007. The net profit of the group was E147.2 million ($216.5 million) in FY2008, a decrease of 2.3% over FY2007.
Scope of the Report
— Provides all the crucial information on Ipsen S.A. required for business and competitor intelligence needs
— Contains a study of the major internal and external factors affecting Ipsen S.A. in the form of a SWOT analysis as well as a breakdown and examination of leading product revenue streams of Ipsen S.A.
-Data is supplemented with details on Ipsen S.A. history, key executives, business description, locations and subsidiaries as well as a list of products and services and the latest available statement from Ipsen S.A.
Reasons to Purchase
— Support sales activities by understanding your customers’ businesses better
— Qualify prospective partners and suppliers
— Keep fully up to date on your competitors’ business structure, strategy and prospects
— Obtain the most up to date company information available
Table of Contents :
This product typically includes the following sections:
SWOT COMPANY PROFILE: Ipsen S.A.
Key Facts: Ipsen S.A.
Company Overview: Ipsen S.A.
Business Description: Ipsen S.A.
Company History: Ipsen S.A.
Key Employees: Ipsen S.A.
Key Employee Biographies: Ipsen S.A.
Products & Services Listing: Ipsen S.A.
Products & Services Analysis: Ipsen S.A.
SWOT analysis: Ipsen S.A.
*Strengths: Ipsen S.A.
*Weaknesses: Ipsen S.A.
*Opportunities: Ipsen S.A.
*Threats: Ipsen S.A.
Company View: Ipsen S.A.
Top Competitors: Ipsen S.A.
Location and Subsidiary: Ipsen S.A.
*Head Office: Ipsen S.A.
*Other Locations and Subsidiaries: Ipsen S.A
For more information, please visit :
www.aarkstore.com/reports/Ipsen-S-A-SWOT-Analysis-22547.html

How the rail recruitment industry works

How the Rail Recruitment Industry Works

In searching for the best talent in the Rail Industry, Rail Recruitment is the obvious answer. With expert rail and engineering specialists, their chances of finding the right person qualified for the job, as well as a good fit for your company might be just an email or phone call away.

For those seeking rail industry jobs, a recruitment service can offer, a better, quicker solution, leading to employment with a fine company, than would otherwise be possible from the little progress one might make searching through every company each day. Both job seekers and Railways Companies benefit financially through the Recruitment process by posting jobs on line at Recruiter websites, for a substantially smaller fee than would be available through a classified ad, then these vacancies are transmitted almost immediately to suitable candidates as The Railway Recruitment Companies search through their database of available possibilities. Suitable candidates are sorted by skill, location and qualifications. Best of all, is a simple, effective way to finding a new or better contract for both the Rail Industry and the Individual.

Most Rail Industry Recruitment Companies follow similar patterns to fill a job vacancy. They begin by posting the available Rail jobs on their industries website, usually a separate webpage with the opportunities location, the jobs requirements, and often the average pay scale. Suitable candidates will be contacted and an interview arranged for.

Next the Recruiter might assess the Candidates deportment in given situations, as well as their qualifications and capabilities. The tools used to determine these things might be psychological, numerical, or Grammar Tests.

Most Railway jobs, if not all, will require a drug and/or an alcohol test. Participation in these test will usually be compulsory to comply with Insurance Standards for the Industry. A Background Check will also be part of the screening.

Once all of these pre-qualificatiions are in place, usually a Rail Industry Recruiters next step will be to contact the applicants references, and if satisfactory, extend an offer to a well qualified candidate. For the recruiters themselves, they become a valuable asset to Rail Industry for the top quality applicants they find; with the added bonus of all the pre-requisites in place. It saves the Rail Industry time, and money, that goes back into the company for the benefit of the whole.

Rail Industry Recruitment benefits both Candidates and Companies equally in this symbiotic relationship.

There are several specialist rail industry recruitment Job Boards and Job Sites, some in the UK and some overseas.

India — private investments scaling up in clinical trial industry

India — Private Investments Scaling Up in Clinical Trial Industry

Clinical trials are considered as one of the most important stages of the drug development and share a major part of the cost and time involved in the whole process. With an increasing pressure on pharmaceutical and biotech companies to increase their product pipelines and at the same time to reduce the cost involved in drug development, multinational pharmaceutical companies have started outsourcing clinical trials to emerging healthcare markets like India. RNCOS, a leading market research firm, says in its new report «Booming Clinical Trials Market in India» that India has tremendous potential to attract multinationals to invest in its clinical trials market. The market is expected to grow at a CAGR of around 31% during 2010-2012.

With the increasing trend of outsourcing clinical trials, the private investments in the sector have also increased. Most of these investments are aimed at setting up clinical trial facilities in the country. Also, it has been observed that some multinationals have made joint ventures with the Indian companies to set up such facilities. In this regard, our research report provides complete information on the current scenario of the Indian clinical trial industry.

One of the other major advantages that India has, is the availability of large patient pool. The prevalence of diseases, like CVD, diabetes and cancer, is very high in the country, and this makes the availability and administration of patients for clinical trials very easy. Our research provides a thorough study and analysis of the Indian clinical trial industry. Besides, the report has also highlighted the importance of cost factor in the development of the industry and it provides complete details of the cost involved in various phases of clinical trials in the country.

«Booming Clinical Trials Market in India» gives a comprehensive review of the Indian clinical trial industry. Thorough evaluation of current trends and developments vital for the success of Indian clinical trials market has been done. The report also covers information on various major players present in the market. The report will prove to be a useful investment guide for our clients who are looking forward to invest in the market.

For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM564.htm

Check DISCOUNTED REPORTS on: http://www.rncos.com